Pharmacological LRRK2 kinase inhibition induces LRRK2 protein destabilization and proteasomal degradation
Open Access
- 23 September 2016
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 6 (1) , srep33897
Abstract
Leucine-rich repeat kinase 2 (LRRK2) kinase activity is increased in several pathogenic mutations, including the most common mutation, G2019S and is known to play a role in Parkinson’s disease (PD) pathobiology. This has stimulated the development of potent, selective LRRK2 kinase inhibitors as one of the most prevailing disease-modifying therapeutic PD strategies. Although several lines of evidence support beneficial effects of LRRK2 kinase inhibitors, many questions need to be answered before clinical applications can be envisaged. Using six different LRRK2 kinase inhibitors, we show that LRRK2 kinase inhibition induces LRRK2 dephosphorylation and can reduce LRRK2 protein levels of overexpressed wild type and G2019S, but not A2016T or K1906M, LRRK2 as well as endogenous LRRK2 in mouse brain, lung and kidney. The inhibitor-induced reduction in LRRK2 levels could be reversed by proteasomal inhibition, but not by lysosomal inhibition, while mRNA levels remained unaffected. In addition, using LRRK2 S910A and S935A phosphorylation mutants, we show that dephosphorylation of these sites is not required for LRRK2 degradation. Increasing our insight in the molecular and cellular consequences of LRRK2 kinase inhibition will be crucial in the further development of LRRK2-based PD therapies.Keywords
This publication has 56 references indexed in Scilit:
- Discovery and Preclinical Profiling of 3-[4-(Morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile (PF-06447475), a Highly Potent, Selective, Brain Penetrant, and in Vivo Active LRRK2 Kinase InhibitorJournal of Medicinal Chemistry, 2014
- Leucine-rich repeat kinase 2 inhibitors: a review of recent patents (2011 – 2013)Expert Opinion on Therapeutic Patents, 2014
- In silico, in vitro and cellular analysis with a kinome-wide inhibitor panel correlates cellular LRRK2 dephosphorylation to inhibitor activity on LRRK2Frontiers in Molecular Neuroscience, 2014
- Lack of Correlation between the Kinase Activity of LRRK2 Harboring Kinase-Modifying Mutations and Its Phosphorylation at Ser910, 935, and Ser955PLOS ONE, 2014
- Leucine-rich repeat kinase 2 inhibitors: a patent review (2006 – 2011)Expert Opinion on Therapeutic Patents, 2012
- Phosphorylation of LRRK2: from kinase to substrateBiochemical Society Transactions, 2012
- LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in miceHuman Molecular Genetics, 2011
- Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2Nature Chemical Biology, 2011
- Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's diseaseNature Medicine, 2010
- Leucine-Rich Repeat Kinase 2 Mutations and Parkinson's Disease: Three QuestionsASN Neuro, 2009